Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CHHT-Alvotech JV Signs China Deal to Commercialize Biosimilars

publication date: Nov 24, 2020

The China biosimilar JV formed by Changchun High & New Technology and Iceland's Alvotech has signed up Yangtze River Pharma to commercialize their eight biosimilar candidates in China. The JV, CAHT, will manufacture the products. CAHT is developing biosimilar candidates for autoimmunity, ophthalmology, and oncology diseases, plus immune and inflammatory conditions. Established in 2019, CAHT was funded with $110 million in capital at a $200 million valuation. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital